Hetero Head On Remdesivir Partnering, Royalty Model

At Least Eight Bangladesh Firms Now In Fray

Hetero is one of the new licensees for Gilead’s remdesivir, the investigational antiviral in the spotlight as a potential treatment for COVID-19, and the Indian group’s managing director shares insights on its supply chain readiness and the royalty model of the deal.

Hand Shake — Remdesivir Licensee Hetero Shares Insights On Gilead Deal • Source: Shutterstock

Hetero Drugs Ltd. has been a long-standing Gilead Sciences Inc. licensee, including for the US firm’s HIV and hepatitis C therapies in the past, and the Indian company says such established relationships matter when sewing up critical pacts such the new alliance for remdesivir, the antiviral that has already received US Emergency Use Authorization to tackle COVID-19.

Earlier this week, Gilead sealed non-exclusive voluntary licensing agreements with five generic firms in India and Pakistan, including Hetero, to manufacture remdesivir for distribution in 127 countries.(Also see "Gilead Licensing Deal Expands Remdesivir Access, Capacity" - Scrip, 13 May, 2020

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

12 May 2025

• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Dr Reddy’s Gears For Tariffs Scenario, To Ensure No US Supply Disruption

12 May 2025

• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Quick Listen: Scrip’s Five Must-Know Things

12 May 2025

• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.

Takeda Plans US Investment But Sees Little Impact From Tariffs

09 May 2025

• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor Into Phase III For IPF

12 May 2025

• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.